Relevium Announces Revenue of $3.2M for the Nine-Month Period Ended March 31, 2018
Momentum Public Relations
Press Release: May 30 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”) is pleased to announce its financial and operating results for the three and nine months’ period ended March 31, 2018.
Highlights
- Nine-month sales totalled $3,157,644 including Q3 sales of $1,063,176 recorded by Bioganix®
- Nine-month gross profit of $1,806,515 (57%), including Q2 gross profit of $575,495 (56%)
- In this reporting period, the Company:
- Initiated a market test for the eventual launch of a complete Aloe Vera based health support products and cosmetics
- Revealed a new brand architecture for Bioganix®
- Conducted the initial joint-launch of Planet Hemp with HEMPCO
- Established its presence for the European marketplace in partnership with Amazon
- The Company increased product offerings by 17% to 38 products with further plans to expand to over 50 products in 2018
Results from Operations
During the nine-month period ended March 31, 2018, the Bioganix brand generated $3,157,644 in sales revenues with a gross profit of $1,806,515. A gross margin of 57% continues to remain stable and adjusted EBITDA for the brand remains positive at 25%. On a consolidated basis, the Company reported an increase in expenses in three key areas:
- Selling and Marketing Expenses: The reporting period was marked by a period of preparation for market expansion, which included increased expenses relating to initiatives to build brand equity, expand geographically, launch of new products and build the operating team. The investments included brand repositioning and branding services, promotions and new product launches, increased digital marketing campaigns and other value-added services. The total marketing expense for the nine-month was reported at $1,252,668 with $313,167 allocated to market expansion, branding and product launch initiatives.
- Interest and Accretion Expenses: The Company reported a total of $612,040 ($348,422 of interest and $263,618 of accretion) in the nine-month reporting period for servicing the long-term convertible debt currently on the balance sheet.
- Share-based compensation: The Company reported $554,110 non-cash share-based compensation, reflecting stock options issued to directors, consultants and management in the reporting nine-month period.
These three key areas represent $2,418,818 or 67% of all the Company’s operating expenses for the nine-month reporting period. The Company reported net and comprehensive losses of $1,787,985 ($566,070 in 2017) and Adjusted Earnings Before Interest, Taxes and Amortization totaling $384,151 in the same period.
Aurelio Useche, President and CEO of Relevium stated: “We have increased our marketing and sales spend significantly to successfully launch a new brand, new products and to expand into new markets as previously announced.” Mr. Useche stated further: “Revenues from the original Bioganix product line remain as expected and believe that the additional investments will bear fruit once our presence in Amazon UK and Walmart.com is strong and the new products have taken hold within our customer base.”
For more information, the Company’s previous filings may be reviewed by visiting www.sedar.com and also our website www.releviumtechnologies.com.
Adjusted EBITDA and Non-IFRS Financial Measures
The Management Discussion and Analysis for the same period includes certain measures which are not defined terms in accordance with IFRS such as Adjusted EBITDA. The term “Adjusted EBITDA” refers to net income or net loss after adjusting for interest, taxes, depreciation and costs relating to acquisitions and their integration.
The Company believes that Adjusted EBITDA is useful, supplemental information as it provides an indication of the results generated by the company’s main business activities prior to taking into consideration how those activities are financed and taxed and prior to taking into consideration depreciation and particularly the costs of integration of acquisitions.
Adjusted EBITDA is also a key measure used by the Company’s management and its Board of Directors to understand and evaluate the Company’s operating performance, to prepare annual budgets, and to help develop operating plans. Adjusted EBITDA is not a measure of performance under IFRS and should not be considered in isolation or as a substitute for net and comprehensive income or loss prepared in accordance with IFRS or as a measure of operating performance or profitability.
Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
See “Adjusted EBITDA and Non-IFRS Financial Measures”
- Published in Relevium Technologies
Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March
Momentum Public Relations
Press Release: April 3 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to report an all-time record high in unit sales for the month of March 2018.
The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established product line, which is expected to translate into sales in excess of $439,000 for the month of March. The monthly high did not include the effect from new product launches, which are expected to have an incremental positive impact over the next six months.
The company’s all-time record high of units sold is an important achievement for Relevium’s Bioganix®brand. The Company continues to increase its subscriber base and number of SKUs, now totaling over 230,000 and 38 respectively.
Impact on the Business
- Increase of Bioganix® demand sets the stage for successful launch of new products
- The results indicate that the company’s investment in Mach 2.0 Marketing Engine is starting to pay dividends
Impact on Shareholders
- Increased confidence that management remains engaged on delivering sustainable value to its brands, customers and shareholders
- Incremental value to the acquired Bioganix® business through increased brand equity, exclusive product lines and geographic expansion
- Relevium is steadily building solid base for shareholder value creation, which will deliver future dividends
Abis Hussain, SMO of Relevium, stated: “The implications of this may seem trivial, but the results form this month in a seasonally low period indicate that Mach 2.0 is working as designed. We expect this to also have a positive impact on new products launches over the next six months.”
Aurelio Useche, CEO of Relevium, stated: “This is the first real test of the capabilities of our marketing engine following months of adjustments and beta testing. This small but important success is an important achievement for the company and for our digital marketing and operating teams.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Relevium Operational Update and Investments for Financial H1 2018
Momentum Public Relations
Press Release: February 28 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is reporting on an operational update and areas of investment for financial Q2 2018 (October 1, 2017 to December 31, 2017).
Aurelio Useche, President and CEO of Relevium stated: “The integration, optimization and scale up of BioGanix since acquisition has gone as expected.” Mr. Useche continued: “Operationally we expected a learning curve and expected to overcome all challenges. I think the Operations Team has overcome all challenges and the Company is poised to drive growth in the 2018 calendar year. The e-commerce landscape for nutraceuticals is under constant change and we have been quick on our feet to adapt and maintain sales velocity.”
During the first six (6) months of operating BioGanix, the Company has focused on transitioning the business, accounts and assets. Following the successful transition which lasted until roughly November 1, 2017, the Company built up an internal Operations Team which subsequently set forth to optimize the business predominantly through conceptualization and deployment of the Mach 2.0 Marketing Engine. During this period, the Company did experience a temporary decrease in revenue.
Since October 1, 2017 the Company has invested over CAD $250,000 for building out the infrastructure and acquiring the talent necessary to drive future growth of the BioGanix brand. These investments in technology, people and commercial agreements will also be integral in allowing the Company to execute on the plethora of product and brand launches it has planned for the 2018 calendar year.
The Company expects to launch no less than three (3) new brands and over twenty (20) new products or SKUs in 2018. Launches will begin as soon as March 2018. The Company will provide further detail to this effect in a forthcoming news release.
Mr. Abis Hussain, Senior Marketing Officer of Relevium Technologies: “We are really excited to start launching products. The Company has yet to launch products that fully reflect our collective efforts. The products that we will bring to market this year will really show our ability to find and market exclusive products. Prior to this, everything being marketed was part of the classic line launched by the previous BioGanix team. We believe our true colors and grit are about to shine.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Relevium Technologies Inc. has provided further clarifications on its press release from earlier on Feb. 23, 2018.
The company has received several requests from active shareholders to clarify ambiguity in the language of the operational press release from earlier in the day.
Aurelio Useche, president and chief executive officer of Relevium, stated, “The company is very appreciative of the feedback from its shareholders who asked us to provide clarity over the press release.”
The first six months of operations have been successful in all fronts, including sales revenue, which have continued to demonstrate an overall positive direction ahead of previous periods.
The company did highlight in the previous news release a revenue decline, which was in reference to the month of November. The decline was related to product adjustments and changes in marketing costs due to the implementation of the automation process. However, overall revenues for the six-month period were on target.
The following is a summary of the message that was intended by the company to communicate to shareholders:
- The integration, optimization and scale-up of BioGanix since acquisition have been successful and as expected. The transition period included an expected learning curve, and the operating team has done very well in meeting the challenge.
- Sales revenues are on target and ahead of last year’s results by the previous ownership.
- The company has made several important investments, not only to optimize current operations, but also to prepare the team for organic and acquisition-based growth.
The following were also important updates management felt key to convey to its shareholder base:
- The eventual launch of three new brands, the culmination of the successful exclusivity agreements entered into by the company during the reporting;
- The launch of over 20 new products or SKUs (stock-keeping units) in 2018 expected to hit the shelves as soon as March, 2018.
Management looks forward to reporting Q2 2018 financial results next week.
- Published in Relevium Technologies